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Abstract: Lung cancer is the leading cause of cancer deaths in Europe and around the world. Although
available therapies have undergone considerable development in the past decades, the five-year survival
rate for lung cancer remains low. This sobering outlook results mainly from the advanced stages of
cancer most patients are diagnosed with. As the population at risk is relatively well defined and early
stage disease is potentially curable, lung cancer outcomes may be improved by screening. Several studies
already show that lung cancer screening (LCS) with low-dose computed tomography (LDCT) reduces
lung cancer mortality. However, for a successful implementation of LCS programmes, several challenges
have to be overcome: selection of high-risk individuals, standardization of nodule classification and
measurement, specific training of radiologists, optimization of screening intervals and screening duration,
handling of ancillary findings are some of the major points which should be addressed. Last but not
least, the psychological impact of screening on screened individuals and the impact of potential false
positive findings should not be neglected. The aim of this review is to discuss the different challenges of
implementing LCS programmes and to give some hints on how to overcome them. Finally, we will also
discuss the psychological impact of screening on quality of life and the importance of smoking cessation.
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Introduction
Lung cancer is the first cause of cancer-related mortality 
worldwide (1). In Europe, the incidence of lung cancer is 
alarmingly increasing in women, with now more deaths 
due to lung cancer than to breast cancer. Although it is 
beginning to decrease, the number of lung cancer deaths is 
still very high among men (2). In contrast to the increase 
in survival for most cancer types, advances have been slow 
for lung cancer, because the majority of cases are diagnosed 
at an advanced stage (3). There is a potential for earlier 
lung cancer diagnosis through screening with low-dose 
computed tomography (LDCT). In 2011, the National 
Lung Screening Trial (NLST), a large randomized US 
trial, reported a 20% relative reduction in lung cancer–
specific mortality after 7 years of follow-up in the LDCT 
arm (4). This was at the cost of a high false positive rate, 
with 24% of screenings classified as positive of which 
96% were proven to be falsely positive (4). Indeed, all CT 
scans showing at least one non calcified 4 mm nodule were 
considered as positive screens (4). More recently, three 
European trials have confirmed the benefit of screening by 
also demonstrating a reduction of lung cancer mortality 
through screening (5-7). The Multicentric Italian Lung 
Detection (MILD) trial showed a 39% reduced risk of 
lung cancer mortality at 10 years and demonstrated that 
prolonged screening beyond 5 years achieves a higher lung 
cancer mortality reduction compared to the NLST trial (5). 
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The German LUSI (Lung cancer Screening Intervention) 
trial revealed significant reductions in lung cancer mortality 
among women who underwent LDCT (6). Lastly, the 
Dutch and Belgian NELSON trial reported a mortality 
reduction of 24% in men and 33% in women (7). The 
adopted volumetry-based nodule management strategy 
allowed reducing the false positive rate to only 1.2%. The 
reinforced evidence combined to an optimized screening 
strategy make the implementation of LDCT screening 
quite likely. However, there are many challenges to be met: 
It is crucial to ensure that screening is done with the same 
level of quality as in the studies that have demonstrated its 
value, and to obtain adherence of the high-risk population. 
Optimization of the screening intervals is also of major 
importance. Nodule management should aim to reduce the 
risk of overdiagnosis, optimize the effectiveness of screening 
and minimize the participants’ anxiety. This article 
will review the prerequisites necessary for a successful 
implementation of screening and will reassess the influence 
of screening on smoking cessation. 
Adherence of high-risk individuals
One of the big challenges in lung cancer screening (LCS), 
and screening programs in general, is to reach the target 
group since the effectiveness of screening strongly depends 
on the engagement of an at-risk population (8). This can 
be done either by public information campaigns on LCS 
or by targeted patient information through the general 
practitioner. It is mandatory to explain to the participant 
the importance of LCS, the different examination steps 
involved and how long the examinations will take. 
Further, it is important to explain to the participant the 
difference between a “screening” CT and a “standard” 
CT with regard to radiation exposure and diagnostic 
quality. The perception of lung cancer is different from 
that of other cancers. Smokers feel stigmatized or even 
guilty about smoking. In a prospective nationwide survey 
conducted in France and published in 2015, lung cancer 
was characterized by a greater feeling of guilt compared 
with breast cancer, being more frequently considered as 
a punishment (9). It is important to present screening 
not with negative terms but in a positive way that can be 
accepted by the participants. Rather than using the term 
LCS, the Manchester implementation study chose to name 
their screening programme ‘lung health checks’ which is 
more positive and less frightening. Indeed, participants 
might be afraid to be diagnosed with a lung cancer. 
According to the authors, this term has been one of the 
keys to their success. They managed to screen 1,384 of the 
1,423 identified high-risk individuals (10). Conversely, a 
report by Jemal et al. indicated that in 2015, only 4% of 
the 6.8 million eligible Americans reported being screened 
for lung cancer with low‐dose computed tomography (11). 
Another study found that more individuals who did not 
meet guideline‐recommended criteria for LCS had received 
a recent test than those who did meet criteria (12). Efficient 
implementation will require acquainting physicians with 
eligibility criteria for LCS. This information should also 
be delivered through large public information campaigns, 
using positive terms, and avoiding smokers’ stigmatization. 
Optimization of the population to be screened
Selection of the population to be screened on a priority 
basis is important, for cost effectiveness. Participants should 
at least meet the eligibility criteria of the LCS studies 
which have proven the benefits of screening. These criteria, 
based on age and smoking history, show small differences 
according to the different screening studies. Participants 
of NLST were 55 to 74 years old with 30 or more pack-
years of cigarette smoking history (13). Those included in 
the NELSON study were 50 to 75 years old and smoked 
15 cigarettes or more per day for at least 25 years or at least 
10 cigarettes per day for at least 30 years (14). Other studies 
used risk prediction models considered more accurate in 
identification of high-risk individuals for screening than 
eligibility criteria based on age and smoking (15). Selection 
of participants in the UKLS study (16) was based on the 
Liverpool Lung Project (LLP)v2 model (17), whereas the 
Prostate, Lung, Colorectal and Ovarian Cancer Screening 
Trial (PLCO) 2012 (18) model was used in the Manchester 
pilot study (10) and the PanCan model in the PanCan 
study (19). Higher lung cancer prevalence was reported 
at baseline in these studies, as compared to the NLST 
and NELSON studies, with 2%, 3% and 5% prevalence 
and 85%, 80% and 77% early stages, respectively 
(17-19). However, selection of individuals at higher risk 
might not increase cost-effectiveness. An analysis performed 
in the NLST population reported that participants at 
greater risk for lung cancer mortality were older and had 
more comorbid conditions and higher screening-related 
costs (20). Regarding the role of serum and blood-based 
biomarkers for LCS, such as micro RNAs or tumor-
associated autoantibodies, a 2018 systematic review 
concluded that there is currently no evidence to support 
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their implementation in clinical practice (21). There are 
ongoing phase 4 studies, to evaluate the clinical and cost 
effectiveness of auto-antibodies (EarlyCDT®-Lung Test) 
for early lung cancer detection (22), or combining miRNA 
signature and LDCT, such as in the bioMILD study 
(ClinicalTrials.gov ID: NCT02247453) evaluating miRNA 
signature classifiers (MSC) in conjunction with LDCT.
Screening interval and duration of screening
Unlike NLST, where the screening interval was annual, 
the NELSON study used increasing intervals, first one 
year, then two years and finally two and a half years. More 
interval cancers were observed between the last two rounds 
of screening, 2.5 years apart (23). Furthermore, the MILD 
study compared in a randomized approach an interval of  1 
or 2 years between CT screenings and reported the same 
reduction in mortality with biennial screening (24). It can 
be deduced from these data that a 2-year interval should not 
be exceeded between two controls. Adjusting the screening 
interval based on findings at previous CT screening could 
be an option (6). Participants with negative screen results 
and neither emphysema nor consolidation could benefit 
from longer screening intervals (6). Another approach 
for defining the screening interval between follow-up 
studies after baseline is the use of biomarkers (25). Genetic 
predisposition together with the detection of lung cancer 
metabolites excreted in the urine, blood, sputum or even 
exhaled breath are promising factors for identifying high-
risk candidates for whom screening intervals could be 
reduced (26-30). Despite the potential of the molecular 
approach, no molecular biomarkers for lung cancer are 
currently used in routine clinical practice (25). Further 
studies are needed for the validation and standardisation of 
molecular biomarkers before they can be integrated in LCS 
protocols.
At what age should the screening stop? The US 
preventive service task force (USPSTF) recommends annual 
screening in adults aged 55 to 80 years (31). The upper age 
limit is therefore higher than in the NELSON and NLST 
studies.
Quality of screening, radiologists’ expertise
If screening were to become widespread, there would 
be a shortage of expert thoracic radiologists to read 
the LDCT scans, and a double reading by experts, as 
carried out in European studies, does not seem realistic 
for large-scale screening. This is the reason why the 
European Society of Thoracic Imaging (ESTI) prepared 
a dedicated training programme named Lung cancer 
screening (LCS) certification project (32), endorsed by 
the European Society of Radiology (ESR), to train general 
radiologists in screening. Indeed, LCS should be practiced 
at a similar quality level to the trials that have proven its 
value, in order to ensure that there is maximal benefit 
from its introduction. In addition to webinars, e-learning 
and workshops on lung nodule management and use of 
computer-assisted tools, technical requirements have been 
elaborated together with a structured report template. The 
implementation of screening should be accompanied by 
quality control assurance to ensure that the radiation dose is 
optimized and that the number of positive screenings does 
not exceed what is expected. Indeed, the high sensitivity of 
CT and the high prevalence of lung nodules lead to a high 
risk of false positives. Regarding the false negative risk, it 
has been demonstrated that computer aided diagnosis (CAD) 
has higher sensitivity than double reading by radiologists, 
at the cost of an increased false positive rate (33). The 
development of deep learning offers new perspectives. A 
recent report compared the performance of a deep learning-
based algorithm, trained on NLST dataset to human readers 
and reported on-par performance with radiologists, or even 
higher performance when there was no previous available 
CT exam for comparison (34). Even though prospective 
validation is still lacking, this offers new perspectives, 
with the possibility to optimize the screening process via 
computer assistance and automation. 
Management of screen-detected nodules, 
limitation of the overdiagnosis risk
Two different approaches to nodule management have 
been used in LCS studies, a diameter-based approach as 
in the NLST study, or a volume-based approach for solid 
nodules, as for example in the NELSON trial (4,23). The 
diameter-based approach used in the NLST where every 
non-calcified nodule of at least 4 mm was considered as 
a positive screen, resulted in a high proportion of false 
positives and a low positive predictive value (4). In order 
to reduce the false positive rate, the 4 mm threshold value 
has been raised to 6 mm in lungRADS, which retains a 
diameter-based approach. European trials, especially the 
NELSON trial, have opted for a volumetric approach where 
intermediate volume nodules are re-evaluated in the short 
term, with calculation of their volume doubling time (23). 
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Solid nodules with volume doubling time of more than 
600 days were considered as a negative screen result in the 
NELSON, LUSI and MILD trials (5,23,35). This resulted 
in a much lower false positive rate, being only 1.2% in the 
NELSON study (23). Post hoc analysis of the NELSON 
results led to reconsider the initial volume thresholds 
defining negative and positive screen results (36). The initial 
values of 50 and 500 mm3 should be replaced by 100 and 
300 mm3, and these values are the recommended thresholds 
of the EUPS guidelines (37). The volume doubling time 
strategy is not only a way to limit false positives, it also 
limits the overdiagnosis risk (38), defined as the risk of 
diagnosing a disease that would never be clinically relevant 
within the participants expected lifetime. It is now well 
admitted that some lung cancers are indolent in nature, 
particularly those presenting as ground glass nodules, 
whose doubling times exceed 800 days (39). Diagnosis and 
treatment of these indolent lung cancers should be avoided 
and represents the major burden of overdiagnosis. Long-
term active surveillance of screen-detected subsolid nodules 
has been demonstrated to be a safe strategy to limit the 
risk of over treatment, as demonstrated by Silva et al. (40). 
These authors analyzed the risk of lung cancer and lung 
cancer-related death in subjects included in the MILD 
trial who had unresected subsolid nodules over a period of 
almost 10 years. They found that participants with subsolid 
nodules had higher risk of developing lung cancer, than 
individuals without lung nodules or those having solid 
nodules (40). However, in 73% of cases, lung cancer did 
not develop from the subsolid nodules but from different 
lung areas, and those arising from the subsolid nodules were 
never the cause of death during the almost 10-year follow-
up period (40). Therefore, subsolid nodules should rather 
be considered as markers of carcinogenic exposure, and 
resection of future more aggressive cancers should not be 
compromised, which means that if resection of a subsolid 
nodule is decided, it should be economical for the lung 
parenchyma and consist of limited resection.
Impact on quality of life
Opponents of screening programmes criticize the high 
socio-economical costs of screening, the radiation burden 
the screened population is exposed to, and last but not 
least the potentially negative psychological effects for the 
participating individual (41). 
The psychological impact of screening on quality of 
life is already a well-known problem of other screening 
programmes, such as for example breast cancer screening 
(42,43). The psychological burden a screening participant 
can go through, consists not only of anxiety related 
to positive or indeterminate results, but includes the 
psychological distress the patient goes through in the 
different phases of screening: (I) before screening, (II) 
during the examination, and (III) after screening while 
waiting for screening results. Altogether, the baseline 
anxiousness a screening patient goes through, paired 
with the psychological burden of the high rate of false 
positive exams, suggests that many patients are at risk for 
unnecessary screening-related distress. This perceived 
psychological distress might affect overall health-related 
quality of life (HRQOL) (42). Symptoms are variable 
between individuals, and can vary by severity from mild 
to severe (42). To date several studies evaluated the 
psychological burden LCS can have on a single individuum 
(44-47). Some studies evaluating the effect of screening 
results on the screened individual showed that a negative 
result led to decreased distress and anxiety while a true 
positive result led to increased anxiety and worse HRQOL 
(44,45). Additional negative factors associated with 
anxiety and increased lung cancer specific distress were 
(I) indeterminate or suspicious results who endorsed high 
perceived risk of lung cancer or (II) patients discomfort 
while waiting for CT screening results (14,46,47). 
Contrary to this, other studies did not report differences in 
HRQOL among participants with false positive and true 
negative results. The NLST analysis of HRQOL and state 
anxiety revealed no differences between participants with 
different screening results (i.e., false-positive, true-positive, 
significant incidental findings) (45). The authors partially 
attributed this result to the extensive counselling that 
study participants received while enrolled in the screening 
programme (45). Altogether, the current scientific evidence 
suggests that LCS has the potential to cause short-term 
psychological burden in individuals with an indeterminate 
scan result, although the adverse effects do not appear to 
persist long-term (1). This is in contrast to the current 
evidence in mammography screening for breast cancer, 
where indeterminate results requiring further investigation 
resulted in short-term increased anxiety which persisted 
long-term for up to three years (43,45,48). In order to 
reduce psychological burden for the participating individual, 
it is important that the participant is accompanied by 
a physician through the screening process: potential 
candidates for screening need to be fully informed about 
the risk of the possible psychological burden and individuals 
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who have been screened should receive clear and detailed 
information on screening results interpretation (46). With 
this approach, the participant will not feel lost in the 
screening process. 
Management of ancillary findings
An ancillary finding can be defined through three 
conditions: (I) it occurs in subjects within a medical study, 
(II) potentially affects the health of the subjects and (III) 
the finding is beyond of the intended scope of the study 
objective (49). In the last years, the number of incidental 
findings has steadily increased (50), due to the widespread 
use of modern imaging modalities such as magnetic 
resonance imaging and computed tomography in clinical 
routine. The detection of an unexpected radiological 
finding can give rise to further diagnostics and therapy. 
While some findings need further work-up, others such as 
a pulmonary hamartoma or a vertebral haemangioma, are 
clearly benign (51). An evaluation of the different screening 
trials, shows that the number of reported screening-related 
ancillary findings is quite variable. The prevalence of 
significant ancillary findings varies from 1% in the Dutch-
Belgian lung cancer screening trial (NELSON) to up to 
19% at a Canadian centre participating in the International 
Ear ly  Lung Cancer  Act ion Program ( I-ELCAP) 
(14,52-54).The most commonly reported incidental findings 
are emphysema and coronary artery calcifications, which 
can be associated to smoking-related disease (55). The 
list of ancillary findings is long, and consists of incidental 
pulmonary findings (chronic obstructive pulmonary disease, 
interstitial lung abnormalities, pulmonary infection), 
incidental pleural findings (pleural thickening, pleural 
plaques), incidental mediastinal findings (thyroid nodules, 
lymphadenopathy, mediastinal masses and pathologies of the 
oesophagus), findings in the upper abdomen (malignancy, 
infections) and conditions of the soft tissues and skeletal 
apparatus (56). The American College of Radiology 
(ACR) included in the CT Screening Reporting and 
Data System (Lung-RADS) a category «S» modifier 
for clinically significant non-lung cancer findings (57). 
It is to the discretion of the radiologist to distinguish 
which findings have little or no clinical consequence and 
which are significant enough to require further evaluation. 
Additionally, this distinction is not only important for 
patient care, but also implicates the appropriate use of 
health care resources (56). Beside, triggering follow-up 
exams and increasing health-care related costs, the detection 
of ancillary findings can also have a positive impact: in 
the NLST beside a 20% reduction in lung-cancer specific 
mortality also a 6.7% reduction in all-cause mortality has 
been reported (52). The reduction of all-cause mortality 
might be explained because imaging from the lower neck 
to the upper abdomen may detect actionable or potentially 
significant ancillary findings in a population at risk for age- 
and smoking-related comorbidities (56). Lastly, ancillary 
findings are not specific to screening, but a known problem 
in radiology and should be handled as such (51). Each 
radiologist or physician should try to balance the diagnosis 
of a condition that might cause morbidity and mortality 
and thereby possibly alter its course against the potential 
to cause harm in the patient by prompting a round of 
unnecessary and dangerous diagnostic tests (51).
Association to smoking cessation 
Smoking plays a causal role in at least over 15 types of 
cancer and is the most important risk factor for developing 
lung cancer (58-60). Additionally, there has been shown a 
causal relationship between continued tobacco consumption 
and all-cause and cancer-specific mortality, higher risk 
of progression, and increased risk for smoking-related 
second primary cancers in oncological patients (61). The 
cancerogenic effect of smoking is well accepted in the 
scientific community and it is self-evident, that patients 
participating in screening programmes should also get 
smoking cessation counselling. Interestingly, participating 
LCS programmes showed different effects on participating 
individuals. A study which evaluated attitudes and 
perceptions about smoking cessation in a group of LCS 
participants (62), observed that patients may substantially 
overestimate the benefit of cancer screening and may have 
misperceptions about the harm reduction itself. Although, 
most screening patients reported an increased perception 
on the harms and long-term consequences of tobacco use, 
half of the evaluated patients reported decreased motivation 
to quit smoking following screening. Reasons for this were 
misperceptions such as “undergoing screening yields the 
same benefits as smoking cessation” and “everyone who 
undergoes screening will benefit” (62). Another study 
evaluating risk perceptions associated with LCS reported 
that most patients understood the link between tobacco-use 
and development of lung cancer and other smoking related 
diseases. However, study participants did not translate 
them into quitting behaviours (15). This phenomenon 
is not exclusive to LCS but has also been described in 
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other screening programmes (63). Contrary to this, a 
recently published observational cohort study investigating 
smoking behaviour and LCS in socio-economically 
deprived populations, found that community-based LCS 
programmes positively impacts smoking behavior, with 
no evidence of misperceptions such ‘screening is a license 
to smoke’ in the participating individuals (64). A study 
evaluating screening participants in the Danish lung cancer 
screening trial (DLCST) found that participants after one 
year of screening showed a significant increase in cessation 
attempts and decrease in relapse to smoking among patients 
with a positive scan versus those with a negative scan (65). 
This effect however, was not observed when all five years 
of screening were analysed (66). Another study reported 
no statistical significant differences in smoking cessation 
attempts and quit rates between smokers who participated 
in a screening programme and a control group that was 
not screened (67). However, also in this trial smokers 
with a positive screening result showed a significantly 
higher number of quit attempts (67) compared to those 
with negative screening results. Similarly, other studies 
suggest (19-22) that any positive, and also false-positive, 
screening result was associated with greater motivation 
to quit smoking and a higher likelihood of quitting and 
sustained abstinence. Although, there is evidence that 
individuals undergoing screening programmes may quit 
at slightly higher rates than the general population of 
smokers (68), this might not necessarily being attributed to 
the screening programme itself, but may also be partly due 
to demographic or motivational differences in populations 
willing to undergo screening (69). Overall, smoking 
cessation remains the most harmless and cost effective 
manner to reduce lung cancer related mortality and 
therefore smokers participating in screening programmes 
should be carefully counselled to ensure that screening itself 
is not perceived as an adequate replacement for smoking 
cessation (42,70).
Conclusions
LCS will inevitably be implemented in Europe. It is 
essential to train general radiologists and define the reading 
modalities which would be efficient and realistic for large 
scale screening. The role of artificial intelligence remains 
to be prospectively validated. Screening individuals at 
higher risk of lung cancer, based on the use of risk models, 
will increase screening effectiveness but not necessarily 
cost-effectiveness. Implementation research programmes 
could help to improve the screening process (71). Quality 
assurance needs to be implemented and a European registry 
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